Unstable angina/ NSTEMI resident survival guide: Difference between revisions
Line 60: | Line 60: | ||
{{familytree | | | | | C01 | | | | | | C02 | | C01= LOW RISK <br> Initial conservative strategy| C02= HIGH RISK <br> Initial invasive strategy}} | {{familytree | | | | | C01 | | | | | | C02 | | C01= LOW RISK <br> Initial conservative strategy| C02= HIGH RISK <br> Initial invasive strategy}} | ||
{{familytree | | | | | |!| | | | | | | |!| | | }} | {{familytree | | | | | |!| | | | | | | |!| | | }} | ||
{{familytree | | | | | D01 | | | | | | D02 | | D01= ❑ Administer 300mg of copidogrel <br> ❑ Administer | {{familytree | | | | | D01 | | | | | | D02 | | D01= ❑ Administer 300mg of copidogrel <br> ❑ Administer fondaparinaux<ref name="pmid16537663">{{cite journal| author=Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J et al.| title=Comparison of fondaparinux and enoxaparin in acute coronary syndromes. | journal=N Engl J Med | year= 2006 | volume= 354 | issue= 14 | pages= 1464-76 | pmid=16537663 | doi=10.1056/NEJMoa055443 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16537663 }} [http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16944851 Review in: ACP J Club. 2006 Sep-Oct;145(2):30-1] </ref> | ||
or UFH in case of renal failure | or UFH in case of renal failure | ||
|D02= ❑ Administer IV GP IIb/IIIa inhibitors (eptifibatide or tirofiban) <br> OR <br> ❑ Administer Bivalirudin}} | |D02= ❑ Administer IV GP IIb/IIIa inhibitors (eptifibatide or tirofiban) <br> OR <br> ❑ Administer Bivalirudin}} | ||
Line 82: | Line 82: | ||
❑ Continue aspirin + UFH <br> | ❑ Continue aspirin + UFH <br> | ||
❑ Discontinue clopidogel 5 days before <br> | ❑ Discontinue clopidogel 5 days before <br> | ||
❑ Discontinue enoxiparin and | ❑ Discontinue enoxiparin and fondaparinaux 12-24 hrs before <br> | ||
❑ Discontinue IV GP inhibitors 4 hrs bfore <br> | ❑ Discontinue IV GP inhibitors 4 hrs bfore <br> | ||
❑ Discontinue bivalirudin 3 hrs before }} | ❑ Discontinue bivalirudin 3 hrs before }} | ||
Line 98: | Line 98: | ||
❑ Continue aspirin + UFH <br> | ❑ Continue aspirin + UFH <br> | ||
❑ Discontinue clopidogel 5 days before <br> | ❑ Discontinue clopidogel 5 days before <br> | ||
❑ Discontinue enoxiparin and | ❑ Discontinue enoxiparin and fondaparinaux 12-24 hrs before <br> | ||
❑ Discontinue IV GP inhibitors 4 hrs bfore <br> | ❑ Discontinue IV GP inhibitors 4 hrs bfore <br> | ||
❑ Discontinue bivalirudin 3 hrs before}} | ❑ Discontinue bivalirudin 3 hrs before}} |
Revision as of 20:17, 27 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Definition
Unstable angina is an unexpected chest pain while resting or sleeping,that could get worse with time lasting at least 20 minutes up to 30 minutes. It is caused by a temporary reduced blood flow, resulting in a decreased oxygen supply to the myocardial tissue.
Causes
Life Threatening Causes
- Reduced myocardial perfussion
- Mycordial infarction
- Cocaine-associated mycoardial infarction
Common Causes
- Atherosclerosis
- Non-occlusive thrombus
Management
Diagnosis
CHARACTERIZE THE SYMPTOMS ❑ Chest pain or discomfort while resting ❑ The pain is longer than 20 minutes | |||||||
PERSONAL HISTORY ❑ Age | |||||||
PHYSICAL EXAMINATION ❑ Measure blood pressure | |||||||
LABS & TESTS ❑ EKG | |||||||
Treatment
❑ Administer 300mg Aspirin immediately after hospital admission[1] ❑ Administer oxygen in patients with saturation <90% | |||||||||||||||||||||||||||||||||||||||||
Determine Risk of adverse coronary event (TIMI) | |||||||||||||||||||||||||||||||||||||||||
LOW RISK Initial conservative strategy | HIGH RISK Initial invasive strategy | ||||||||||||||||||||||||||||||||||||||||
❑ Administer 300mg of copidogrel ❑ Administer fondaparinaux[2] or UFH in case of renal failure | ❑ Administer IV GP IIb/IIIa inhibitors (eptifibatide or tirofiban) OR ❑ Administer Bivalirudin | ||||||||||||||||||||||||||||||||||||||||
Perform a Stress test | Angiography | ||||||||||||||||||||||||||||||||||||||||
LOW RISK | HIGH RISK | NEGATIVE | POSITIVE | ||||||||||||||||||||||||||||||||||||||
Recurrent symptoms? | ❑ Continue Aspirin ❑ Continue with clopidrogel or ticagelor for 12 months ❑ Discontinue with GP inhibitors ❑ UFH (for 48hrs) or Enoxiparin[3] (for 8 dyas) | ||||||||||||||||||||||||||||||||||||||||
NO | ❑ Heart failure ❑ Serious arrhythmias ❑ Subsequent isquemia | ||||||||||||||||||||||||||||||||||||||||
Continue Aspirin ❑ Continue with clopidrogel or ticagelor for 12 months ❑ Discontinue with GP inhibitors ❑ UFH (for 48hrs) or Enoxiparin (for 8 dyas | PCI ❑ Administer clopidogrel 24 hrs before | CABG ❑ Continue aspirin + UFH | |||||||||||||||||||||||||||||||||||||||
INTENSIVE STRATEGY - ANGIOGRAPHY | |||||||||||||||||||||||||||||||||||||||||
NEGATIVE | POSITIVE | ||||||||||||||||||||||||||||||||||||||||
❑ Continue Aspirin ❑ Continue with clopidrogel or ticagelor for 12 months ❑ Discontinue with GP inhibitors ❑ UFH (for 48hrs) or Enoxiparin (for 8 dyas) | PCI ❑ Administer clopidogrel 24 hrs before | CABG ❑ Continue aspirin + UFH | |||||||||||||||||||||||||||||||||||||||
Do´s
- Administer 300 mg of clopidogrel as initial treatment instead of aspirin in case of gastrointestinal intolerance of hypersensitivity reaction.
- Oxygen must be administered in patients with arteria saturation less than 90% or in respiratory distress [4]
- Administer sublingual nitroglycerin in patients with ischemic chest pain. IV should be administer in patients with persistent chest pain after three sublingual nitroglycerins. [5]
- Nitroglycerin should be administer to all patients with hypertension or heart failure.
- Beta-bloquers should be administer to all patients with hypertension, tachycardia or ongoing chest pain. [6] [7]
- Statins should be administer to all patients with unstable angina. The recommendation is atorvastatin 80mg/day [8] [9]
- Non-steroidal anti-inflamatory drugs should be discontinued immediately. [10] [11]
- P2Y12 platelet inhibitor therapy should be continued for 12 months with a maintenance dose of either [1]
- Clopidogrel - 75mg per day
- Prasogrel - 10mg per day
- Ticagrelor - 90mg twice a day
Don´ts
References
- ↑ 1.0 1.1 Harrington RA, Becker RC, Cannon CP, Gutterman D, Lincoff AM, Popma JJ; et al. (2008). "Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)". Chest. 133 (6 Suppl): 670S–707S. doi:10.1378/chest.08-0691. PMID 18574276.
- ↑ Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators. Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J; et al. (2006). "Comparison of fondaparinux and enoxaparin in acute coronary syndromes". N Engl J Med. 354 (14): 1464–76. doi:10.1056/NEJMoa055443. PMID 16537663. Review in: ACP J Club. 2006 Sep-Oct;145(2):30-1
- ↑ Antman EM, McCabe CH, Gurfinkel EP, Turpie AG, Bernink PJ, Salein D; et al. (1999). "Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial". Circulation. 100 (15): 1593–601. PMID 10517729.
- ↑ name="pmid23554440">{{cite journal| author=Shuvy M, Atar D, Gabriel Steg P, Halvorsen S, Jolly S, Yusuf S et al.| title=Oxygen therapy in acute coronary syndrome: are the benefits worth the risk? | journal=Eur Heart J | year= 2013 | volume= 34 | issue= 22 | pages= 1630-5 | pmid=23554440 | doi=10.1093/eurheartj/eht110 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?
- ↑ Kaplan K, Davison R, Parker M, Przybylek J, Teagarden JR, Lesch M (1983). "Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy". Am J Cardiol. 51 (5): 694–8. PMID 6402912.
- ↑ Rosendorff C, Black HR, Cannon CP, Gersh BJ, Gore J, Izzo JL; et al. (2007). "Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention". Circulation. 115 (21): 2761–88. doi:10.1161/CIRCULATIONAHA.107.183885. PMID 17502569.
- ↑ López-Sendón J, Swedberg K, McMurray J, Tamargo J, Maggioni AP, Dargie H; et al. (2004). "Expert consensus document on beta-adrenergic receptor blockers". Eur Heart J. 25 (15): 1341–62. doi:10.1016/j.ehj.2004.06.002. PMID 15288162.
- ↑ Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R; et al. (2004). "Intensive versus moderate lipid lowering with statins after acute coronary syndromes". N Engl J Med. 350 (15): 1495–504. doi:10.1056/NEJMoa040583. PMID 15007110. Review in: ACP J Club. 2004 Sep-Oct;141(2):33
- ↑ Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D; et al. (2001). "Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial". JAMA. 285 (13): 1711–8. PMID 11277825.
- ↑ Trelle S, Reichenbach S, Wandel S, Hildebrand P, Tschannen B, Villiger PM; et al. (2011). "Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis". BMJ. 342: c7086. doi:10.1136/bmj.c7086. PMC 3019238. PMID 21224324. Review in: Evid Based Med. 2011 Oct;16(5):142-3
- ↑ Coxib and traditional NSAID Trialists' (CNT) Collaboration. Bhala N, Emberson J, Merhi A, Abramson S, Arber N; et al. (2013). "Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials". Lancet. 382 (9894): 769–79. doi:10.1016/S0140-6736(13)60900-9. PMC 3778977. PMID 23726390. Review in: Ann Intern Med. 2013 Oct 15;159(8):JC12